Difference between revisions of "Aldesleukin (Proleukin)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "[http://www.thomsonhc.com/home/dispatch Micromedex]" to "Micromedex") |
|||
| (18 intermediate revisions by 4 users not shown) | |||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Recombinant interleukin-2 which activates the immune system. | + | Class/mechanism: Recombinant interleukin-2 which activates the immune system. Aldesleukin encourages growth of IL-2 dependent cells, triggers natural killer (NK) and lymphokine-activated killer (LAK) cell activity, induces production of interferon gamma, and increases lymphocyte cytotoxicity.<ref name="insert">[https://www.proleukin.com/downloads/proleukin-pi.pdf Aldesleukin (Proleukin) package insert]</ref><ref>[[:File:Aldesleukin.pdf | Aldesleukin (Proleukin) package insert (locally hosted backup)]]</ref><ref>[http://www.proleukin.com/ Proleukin manufacturer's website]</ref> |
<br>Route: IV | <br>Route: IV | ||
<br>Extravasation: no information | <br>Extravasation: no information | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, [https://online.lexi.com/lco/action/login UpToDate Lexidrug], [http://reference.medscape.com/drug/interleukin-2-proleukin-aldesleukin-342203 Medscape], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> |
| + | |||
| + | ==Diseases for which it is established ''(work in progress)''== | ||
| + | *[[Renal cell carcinoma]] | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
*[[Melanoma]] | *[[Melanoma]] | ||
*[[Neuroblastoma]] | *[[Neuroblastoma]] | ||
| − | |||
==Patient drug information== | ==Patient drug information== | ||
| − | *[ | + | *[https://chemocare.com/druginfo/aldesleukin.aspx Aldesleukin (Proleukin) patient drug information (Chemocare)]<ref>[https://chemocare.com/druginfo/aldesleukin.aspx Aldesleukin (Proleukin) patient drug information (Chemocare)]</ref> |
*[http://www.uptodate.com/contents/aldesleukin-patient-drug-information Aldesleukin (Proleukin) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/aldesleukin-patient-drug-information Aldesleukin (Proleukin) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/aldesleukin-patient-drug-information Aldesleukin (Proleukin) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/aldesleukin-patient-drug-information Aldesleukin (Proleukin) patient drug information (UpToDate)]</ref> | ||
| − | + | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * | + | *1992-05-05: Initial approval for treatment of adults (>18 years old) with metastatic [[renal cell carcinoma]]. ''(Based on Fyfe et al. 1995)'' |
| − | + | *Uncertain date: Approved for the treatment of adults with metastatic [[melanoma]]. ''(Based on Atkins et al. 1999)'' | |
| + | ==History of changes in EMA indication== | ||
| + | *1989-07-03: EURD | ||
| + | ==History of changes in PMDA indication== | ||
| + | *2021-06-23: New indication and a new dosage for the enhancement of an antitumor effect of dinutuximab (genetical recombination) for [[neuroblastoma]]. | ||
==Also known as== | ==Also known as== | ||
| + | *'''Code name:''' ILT-101 | ||
*'''Generic names:''' Interleukin-2, IL-2 | *'''Generic names:''' Interleukin-2, IL-2 | ||
| − | *'''Brand names:''' Macrolin, Proleukin | + | *'''Brand names:''' Macrolin, Proleukin, Teceleukin |
==References== | ==References== | ||
| Line 29: | Line 36: | ||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
| − | [[Category: | + | [[Category:Interleukins]] |
[[Category:T-cell activators]] | [[Category:T-cell activators]] | ||
| Line 37: | Line 44: | ||
[[Category:FDA approved in 1992]] | [[Category:FDA approved in 1992]] | ||
| + | [[Category:EMA approved in 1989]] | ||
Latest revision as of 01:48, 29 June 2024
General information
Class/mechanism: Recombinant interleukin-2 which activates the immune system. Aldesleukin encourages growth of IL-2 dependent cells, triggers natural killer (NK) and lymphokine-activated killer (LAK) cell activity, induces production of interferon gamma, and increases lymphocyte cytotoxicity.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, UpToDate Lexidrug, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is established (work in progress)
Diseases for which it is used
Patient drug information
- Aldesleukin (Proleukin) patient drug information (Chemocare)[4]
- Aldesleukin (Proleukin) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 1992-05-05: Initial approval for treatment of adults (>18 years old) with metastatic renal cell carcinoma. (Based on Fyfe et al. 1995)
- Uncertain date: Approved for the treatment of adults with metastatic melanoma. (Based on Atkins et al. 1999)
History of changes in EMA indication
- 1989-07-03: EURD
History of changes in PMDA indication
- 2021-06-23: New indication and a new dosage for the enhancement of an antitumor effect of dinutuximab (genetical recombination) for neuroblastoma.
Also known as
- Code name: ILT-101
- Generic names: Interleukin-2, IL-2
- Brand names: Macrolin, Proleukin, Teceleukin